Contextual reprogramming of CAR-T cells for treatment of HER2+ cancers.

Zhifen YangLingyu LiAhu TurkozPohan ChenRona Harari-SteinfeldMaggie BobbinOfir StefansonHana ChoiViolena PietrobonBennett AlphsonAngshumala GoswamiVitaly BalanAlper KearneyDharmesh PatelJin YangDamla InelVeena VinodAlessandra CesanoBing WangKyung-Ho RohLei S QiFrancesco M Marincola

Published in: Journal of translational medicine (2021)

As the first application of CRISPRi toward a clinically relevant product, RB-340-1 with the conditional, non-gene editing and reversible suppression promotes CAR-T cells resilience to checkpoint inhibition, and their persistence and effectiveness against HER2-expressing cancer xenografts.

Keyphrases

induced apoptosis
papillary thyroid
cell cycle arrest
dna damage
randomized controlled trial
systematic review
climate change
cell cycle
social support
squamous cell carcinoma
oxidative stress
childhood cancer
combination therapy
depressive symptoms
young adults
pi k akt
smoking cessation